Diagnostic-prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the national specialists on dermatology, venereology and allergology;Postȩpowanie diagnostyczno-profilaktyczno-lecznicze w atopowym zapaleniu skóry. Konsensus grupy roboczej specjalistów krajowych ds. dermatologii i wenerologii oraz alergologii

Polski Merkuriusz Lekarski

Volumn 17, Issue SUPPL. 3, 2004, Pages 3-9

  Gliński, Wiesław ^a   Kruszewski, Jerzy ^b   Silny, Wojciech ^c   Kurzawa, Ryszard ^c   Czarnecka Operacz, Magdalena ^c   Baran, Eugeniusz ^d   Szepietowski, Jacek ^d  

^a Klinika Dermatologiczna Medical University of Warsaw   (Poland)

^b Klin Chorob Infek i Alergologii   (Poland)

^c Zespołu Pediatrycznego ^*

^d Kat/Klin Dermatol   (Poland)

Author keywords

Atopic dermatitis; Prophylaxis; Treatment

Indexed keywords

ACICLOVIR; ALLERGEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN A; EMOLLIENT AGENT; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MICONAZOLE; PIMECROLIMUS; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TACROLIMUS; TRANQUILIZER; ANTIALLERGIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TOPICAL ANTIINFECTIVE AGENT;

ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; DISEASE SEVERITY; HERPES; HUMAN; IMMUNOTHERAPY; MYCOSIS; PHOTOTHERAPY; PRACTICE GUIDELINE; PROPHYLAXIS; PUVA; REVIEW; SLEEP DISORDER; SYMPTOM; ULTRAVIOLET B RADIATION; ADOLESCENT; ADULT; AGE; AGED; CHILD; DISEASE COURSE; DRUG EFFECT; ECZEMA; FEMALE; INFANT; MALE; MIDDLE AGED; NEWBORN; POLAND; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALLERGENS; ANTI-ALLERGIC AGENTS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; ECZEMA; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; POLAND; PRACTICE GUIDELINES; RISK FACTORS;

EID: 13944260533     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Johansson S.G.O., Hourlhane J., Bousquet J. i wsp.: A revised nomenclature for allergy. An EAACI position steatment from the EAACI nomenclature task force. Allergy, 2001, 56: 813-824.
2. Larsen F.S., Holm N.V., Henningsen K.: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J. Am. Dermatol., 1986, 15: 487-494.
3. Lee Y.A., Wahn U., Kehrt R. i wsp.: A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat. Genet., 2000, 26: 470-473.
4. Cookson WOCM, Ubhi B., Lawrence R. i wsp.: Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat. Genet., 2000, 27: 372-373.
5. Bradley M., Soderhal C., Luthman H. i wsp.: Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish poulation. Hum. Mol. Genet., 2002, 11: 1539-1548.
6. Mao X.Q., Shirakawa T., Yoshikawa K. i wsp.: Association of genetic variants of mast cell chymase and eczema. Lancet, 1996, 348: 581-583.
7. Silny W., Czarnecka-Operacz M.: Alergeny powietrznopochodne i ich znaczenie w powstawaniu zmian skórnych u chorych na atopowe zapalenie skóry. Alergia Astma Immunologia, 2001, 6: 81-85.
8. Stadler J. F., Taieb A.: Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology, 1993, 186 : 23-31.
9. Cheril R., Graeber M., Hanifin I.M. i wsp.: Eczema area and severity index (EASI) - a new tool to evaluate atopic dermatitis. W: An emerging new drug for the treatment of atopic dermatitis. Clinical Dermatology 2000, Singapore 1998.
10. Silny W., Czarnecka-Operacz M., Gołȩbka E. i wsp.: Punktowy wskaźnik oceny stanu klinicznego chorych na atopowe zapalenie skóry. Przegl. Dermatol., 1999, 3: 215-222.
11. Szepietowski J.: Atopowe zapalenie skóry: aspekty terapeutyczne. Standardy Medyczne, 2003.
12. Ellis C., Luger T.: International consensus on atopic dermatitis II (ICAAD II): Clinical update and current treatment strategies. Br. J. Dermatol., 2003, 148, supl.63: 3-10.
13. Cisło M.: Zasady leczenia miejscowego. W: Szepietowski J (red). Leczenie chorób akóry i chorób przenoszonych sroga̧. płciowa̧. Warszawa, Wydawnictwo Lekarskie PZWL 2002, 15-39.
14. Białynicki-Birula R., Baran W., Szepietowski J.: Pimekrolimuskrem-nowy niesteroidowy lek przeciwzapalny. Dermatol. Klin. 2004, 6: 103-107.
15. Eichenfield L.F., Lucky A.W., Boguniewicz M. i wsp.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol., 2002, 46: 495-504.
16. Kapp A., Papp K., Bingham A. i wsp.: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteriod anti-inflammatory drug. J. Allergy Clin. Immunol., 2002, 110: 277-284.
17. Kapp A., Allen B.R., Reitano S.: Atopic dermatitis management with tacrolimus ointment (Protopic). J. Dermatol. Treat., 2003, 14, suppl 1: 5-16.
18. Katon N., Hirano S., Yasuno H.: Effects of tacrolimus ointment on facial eruptrion, itch, and scratching in patients with atopic dermatitis. J. Dermatol., 2004, 31: 194-199.
19. Szybejko-Machaj G., Szepietowski J.: Budowa, fizjologia i pielȩgnacja skóry niemowla̧t i małych dzieci. W: Boznański A. (red). Choroby alergiczne wieku rozwojowego. Warszawa, Wydawnictwo Lekarskie PZWL 2003, 161-175.